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Abstract
Stereotactic radiosurgery is related to the history of
“radiotherapy” and “stereotactic neurosurgery”. The
concepts for neurosurgeons and radiooncologists have
been changed during the last decade and have also
transformed neurosurgery. The gamma knife and the
stereotactically modified linear accelerator (LINAC)
are radiosurgical equipments to treat predetermined
intracranial targets through the intact skull without
damaging the surrounding normal brain tissue. These
technical developments allow a more precise intracra-
nial lesion control and offer even more conformal
dose plans for irregularly shaped lesions. Histological
determination by stereotactic biopsy remains the basis
for any otherwise undefined intracranial lesion. As a
minimal approach, it allows functional preservation,
low risk and high sensitivity. Long-term results have
been published for various indications. The impact of
radiosurgery is presented for the management of
gliomas, metastases, brain stem lesions, benign tu-
mours and vascular malformations and selected func-
tional disorders such as trigeminal neuralgia. In AVM’s
it can be performed as part of a multimodality strate-
gy including resection or endovascular embolisation.
Finally, the technological advances in radiation oncolo-
gy as well as stereotactic neurosurgery have led to sig-
nificant improvements in radiosurgical treatment op-
portunities. Novel indications are currently under in-
vestigation. The combination of both, the neurosurgi-
cal and the radiooncological expertise, will help to
minimize the risk for the patient while achieving a
greater treatment success.
INTRODUCTION / HISTORY
The term “radiosurgery” refers to a combination of
principles and methods derived from “radiotherapy”
and “stereotactic neurosurgery”. Stereotaxy is defined
as “operating in a 3-dimensional space with precalcu-
lated directions (trajectories)”. The history of stereo-
taxy is closely connected to the history of neuro-
surgery itself.
Already in 1908 Horsley and Clarke developed the
first stereotactic apparatus in order to precisely locate
the cerebellum of the rat. They included coordinates
from countless brain sections for orientation within
the skull. The next milestone was the development of
a stereotactic system in humans by Spigel and Wycis in
the late 1940’s, designed to treat movement disorders
in humans for the first time. Herein, help-structures
like the foramina of Monroi, the pineal gland and
both the anterior and posterior commissure were de-
fined as targets in the basal ganglia by means of pneu-
matocephalograms [60]. Finally, Lars Leksell and Trau-
gott Riechert, and also Robert and Wells established
frame based stereotactic methods on the basis of co-
ordinates of linear computertomography data. This
technique remains the gold standard for stereotactic
planning up until now [18; 94; 112].
However, with the introduction of new imaging
modalities new frame materials, i.e. titanium, carbon or
ceramics, became necessary [112]. Importantly, the in-
troduction of image fusion software has enabled the
use of combined imaging techniques, i.e. CT, PET,
SPECT, MRI, which further improved the quality and
precision of stereotactic techniques [15; 79; 146; 153].
However, despite the significant progress in the dia-
gnostic accuracy of modern imaging modalities, the
histological determination of brain pathologies re-
mains necessary in most cases, especially if a radiosur-
gical treatment is planned. Reasons for the failure of
stereotactic radiosurgery in achieving an adaequate tu-
mor control include an inadequate visualization of the
tumor, a lack of intraoperative 3-D (volumetric) imag-
ing, or an insufficient or limited dose (e.g. due to prox-
imity to the brainstem) [21; 29; 33; 47; 51; 58; 68; 145;
154].
The principles of radiosurgery were developed in
1951 by Leksell. This technical realization led to the
development of the gamma knife and the stereotacti-
cally modified linear accelerator (LINAC). The gamma
knife and the LINAC are radiosurgical equipments
used to treat predetermined intracranial targets through
the intact skull without damaging the surrounding
normal brain tissue. Gamma knife radiosurgery in-
volves the stereotactic target localization with the Lek-
sell frame and subsequent closed-skull single-treat-
ment session irradiation of a lesion with multiple
highly focused gamma ray beams produced from 60Co
sources. The hemispherical array of sources, the large
number of small-diameter beams, and the steep dose
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plexicity of the physical characterization of the radia-
tion field. LINAC systems appear to be advantageous
in terms of cost, the variety of collimator sizes avail-
able and the sophistication of computerized dose
planning. Currently, further improvements in confor-
mal LINAC treatment techniques are being developed
and implemented, which will further boost the entire
field of radiosurgery by offering even more conformal
dose plans for irregularly shaped lesions. In addition,
LINAC systems are also being adapted for stereotacti-
cally focused fractionated radiotherapy and for stereo-
tactic radiation treatments in other parts of the body
[13; 14; 44; 137].
STEREOTACTIC BIOPSY
There is no doubt that the histological determination
of a brain pathology remains to be a basic necessity
prior to any therapeutic intervention. Knowledge of
the exact histology allows better predictions of the
prognosis of intracranial lesions, to name only one ad-
vantage. Stereotactic biopsy is indicated in the vast
majority of detected intracranial lesions, if not other-
wise defined. Notably, novel, more sophisticated imag-
ing techniques enable the detection of intracranial
pathologies at earlier stages. Consequently, microsurgi-
cal approaches in order to reduce intracranial masses
are required less [5; 7; 12; 27; 32; 36; 55; 83; 108; 110;
111; 147].
A retrospective analysis reviewing 5000 stereotactic
interventions between 1990 and 2005 demonstrated a
diagnostic sensitivity of more than 95% and an overall
complication rate of <3% [138]. This stresses the
growing importance of accurate stereotactic tech-
niques, which allow a safe and secure proof of patho-
logical features.
Moreover, stereotactic principles were the basis for
the development of modern neuronavigational proce-
dures, providing less invasive approaches. Today radio-
surgical techniques, representing minimally invasive
treatment options, are of specific interest to operative
neurosurgeons. Taken together, it is to be expected
that navigation and stereotaxy will become “reunified”
in the near future [24; 48; 71; 96; 133].
METASTASES
Brain metastases occur in one third of all cancer pa-
tients. Without any intervention, the prognosis is quite
poor with a median survival of only one month [39].
Notably, there is an increasing incidence of brain
metastasis as a late complication of extracerebral tu-
mors. Due to the recent improvement in the efficacy
of radiotherapy and chemotherapy for primary tu-
mors, today those metastases commonly determine the
individual prognosis [1; 34; 43; 77; 103; 115; 134; 135].
The constraints of the blood-brain barrier limit the in-
tracranial efficacy of most chemotherapeutic agents
limiting treatment options to surgery, whole brain irra-
diation, or stereotactic irradiation [8].
As previously mentioned,, in recent years the accu-
racy of imaging techniques has been steadily improv-
ing, enabling the detection of metastases at an earlier
stage and at a smaller size. With less morbidity and
mortality as compared to open microsurgical proce-
dures, the non-invasive concepts of radiosurgery pro-
vide an important therapy option for patients with few
lesions. (Fig. 1) [2; 26; 52; 57; 109; 148].
Alternatively, the interstitial brachytherapy with
temporary I125 seeds represents an additional option
for patients suffering from a single metastasis. The
implantation of the seeds can be performed immedi-
ately after confirmation of the diagnosis in the oper-
ating theatre in a single session procedure. Usually
seeds are left in place approximately 25 days and are
removed under local anaesthesia [6; 31; 33; 92; 101;
111; 128].
MALIGNANT GLIOMAS
For patients with malignant glioma clear survival ad-
vantages have been demonstrated with postresection
external beam radiotherapy. However, there is Level I-
III evidence that the use of a radiosurgery boost fol-
lowed by external beam radiotherapy does not confer
benefit in terms of overall survival, local brain control,
or quality of life as compared with external beam ra-
diotherapy alone. Notably, radiotherapeutic doses es-
calating 60 Gy have been shown to solely increase tox-
icity [9; 11; 20; 30; 35; 46; 107; 113; 140; 140]. Never-
thless, for these patients the total resection of >90%
of the “visible” tumor masses, which is defined by
contrast enhanced T1 weighted MRI, is a prerequisite.
Any further “cytoreduction” in terms of incomplete
resection remains out of evidence for outcome and
survival. The inefficiency of current treatment modali-
ties is derived from multiple factors, including the dif-
fusely infiltrative nature of the disease, which limits a
complete surgical resection, the difficulty in overcom-
ing the blood-brain barrier with systemic therapies, and
finally the extreme radioresistant biological nature of
malignant glioma cells. Once more the histological
proof of a malignant glioma is mandatory. The current
standard treatment consists of external beam radio-
therapy combined with concomitant and adjuvant
temozolomide chemotherapy with respect to clinical
and social conditions. The combined and adjuvant ad-
ministration of temozolomide has been proven to be
beneficial in terms of survival in newly diagnosed as
well as recurrent malignant brain tumors [10; 17; 19;
25; 39; 41; 56; 61; 72; 89; 91; 95; 117; 143; 152].
Patients with large tumors causing brainstem com-
pression should be initially managed by a surgical de-
compression of the tumor. Finally, several new
promising targeted agents are being explored as poten-
tial radiosensitizers, which are currently entering early
clinical trials [22].
BRAIN STEM LESIONS
Due to the poor risk-benefit ratio, many lesions of the
brainstem are not being considered for microsurgical
resection. Stereotactic biopsies are considered the
safest and most reliable method for the histological di-
agnosis of intraaxial brain stem lesions. Keeping in
mind the broad variety of possible neoplasias, the de-
finitive pathological diagnosis permits the choice of
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Fig. 1. Stereotactic radiotherapy of a single brain metastasis. A: Visualization of the
target volumes for the treatment of a single intracerebral metastasis of a carcinoma
of the lung (58 y old female, Adeno-Ca, pT2, pN1 (2/8), cM1). A 3D-reconstruction
displaying the metastasis (violett) and proximate sensitive structures (bulbus and
tractus opticus = green and pink; brown = brain stem). B: Visualization of photon
beams for the target volume based on planning CT applying stereotactic frames.
Surrounding isodoses account for 90 percent at 20 Gy. Margins can be reduced to a
minimum with regard to the possibility of exact patient positioning.
Fig. 2. Patient with mask and stereotactic lo-
calizer.
Fig. 3. Patient undergoing stereotactic radio-
surgery.
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with infiltrating tumors of the brainstem, 30 cases
were histologically diagnosed as low-grade astrocy-
tomas, 13 cases as high-grade astrocytomas, 2 cases as
primitive neuroectodermic tumors, 2 cases as rhabdoid
tumors and 1 case as an ependymoma, and 2 patients
with non-specified tumors. No mortality due to
stereotactic biopsies were reported. [27]. In the major-
ity of the patients the histological diagnosis led to a
therapeutic intervention. Thus, due to the low risk of
the procedure, a stereotactic biopsy should be per-
formed in all cases. The radiosurgical treatment of a
brainstem lesion might offer a promising non-invasive
treatment which is not associated with severe sur-
rounding oedema [27; 74; 75; 80; 149].
BENIGN TUMORS
Historically, external beam radiotherapy has been and
is still being extensively applied in the treatment of
malignant and aggressive intracranial tumors and its
important role has been repeatedly verified by im-
proved patient survival and increased tumor control
rates. As more modern therapies are being employed
in surgery and radiotherapy, attention is now also be-
ing directed towards the utility of radiotherapy as ei-
ther primary or secondary treatment of benign prima-
ry brain tumors and meningeomas. Primary tumor
treatment encompasses the irradiation of small benign
tumors without bioptic confirmation of the histologi-
cal tumor type. Secondary treatment involves postop-
erative radiotherapy, with the possibility that less ag-
gressive tumor resections may be performed in areas
with a higher probability of resultant neurological
deficit. Recent studies suggest that this is not only a
possible treatment strategy, but that it may be even su-
perior to a more radical resection strategy in selected
cases [37; 45; 49; 87; 99].
Stereotactic radiosurgery is typically employed as
first line treatment in patients with small to medium
size tumors (without symptomatic brainstem compres-
sions). Furthermore, it is also applied to control the
growth of recurrent or residual tumor after surgical
resection. However, stereotactic radiotherapy, which
represents a non-invasive, hypo-fractionated treatment
strategy, may also be especially suitable for patients
who desire preservation of neurological function
(cochlear, facial nerve) and a high rate of tumor
growth control. Notably, a local tumor control rate of
up to 95% (5y FU) can be achieved [37; 81; 131].
Meningioma control rates range from 90 to 95%, and
the risk of morbidity is low [38; 40; 84; 93; 104]. The
Marseille SRS experience included 1,500 patients, with
1,000 patients having follow-up of more than 3 years.
A long-term tumor control rate of 97%, a transient fa-
cial palsy of less than 1%, and a probability of func-
tional hearing preservation between 50 and 95% could
be achieved in this large series of patients treated with
stereotactic radiosurgery [28; 63; 127].
In another large series of a total of 285 patients, a
local tumor control of 95% was reported (63% regres-
sion, and 32% no further tumor growth). After 15
years the tumor control rate still remained above 90%
at 93.7%. In 5% of the patients a delayed tumor
growth could be identified. A surgical resection was
performed after radiosurgery in 13 patients (5%).
None of the patients developed a radiation-induced
tumor. Eighty-one percent of the patients were still
alive at the time of this analysis with a mean follow-up
time of 10 years [59A]. In patients undergoing treat-
ment for acoustic neuromas, a normal facial nerve
function was maintained in 95% of patients who had
normal function before. Other authors also reported
on comparable results [49; 66; 87].
A further indication for radiosurgical therapy in be-
nign tumors is the interstitial treatment of hypothala-
mic hamartomas with temporarly implanted iodine
seeds (also called brachytherapy). These tumors often
become symptomatic with gelastic seizures. Schulze-
Bohnhage et al. found that 11 out of 24 patients were
seizure free or experienced a seizure reduction of at
least 90% after a mean follow-up period of 24-months
following the last interstitial radiosurgical treatment.
Notably, the duration of epilepsy prior to radiosurgery
negatively influenced this outcome. Moreover, also
seizure-patients who present at younger ages (<15 y)
can be successfully treated with brachytherapy. I125
seed implantation as a radiosurgical technique is pre-
dominantly applied for this indication due the advan-
tage of continuous dose application and the possibility
of immediate interruption of therapy in cases of side
effects, e.g. alteration of the optical tract [4; 42; 73;
123; 129; 130; 141].
AVM
Radiosurgery has been proven to be succesful in the
treatment of small arteriovenous malformations
(AVMs) of the brain [16; 85; 139; 142; 144; 150]. Until
now, digital subtraction angiography (DSA) has been a
mandatory tool for the planning of these interven-
tions. By integrating different imaging modalities in
the planning and follow-up procedure, e.g. MRI, many
side effects can be avoided [64]. However, due to the
often significant volume of healthy tissue being irradi-
ated in cases of larger AVM lesions, reduced radiation
doses would be preferable in order to minimize the
rate of irreversible radiation injuries. On the other
hand, lower radiation doses lead to lower obliteration
rates. Thus, several strategies have been developed in
the past decade to overcome these dose-volume prob-
lems with larger AVMs, including reduced prescription
doses, volume fractionation and fractionated stereo-
tactic radiotherapy treatments. AVMs with a volume of
~ >3 ml can be completely obliterated (obliteration
rate 72-96%) [76], whereas in larger AVMs complica-
tion rate and obliteration rate still remain unsatisfacto-
ry, especially in AVM’s >10ml. [114]. However, recent
optimistic reports suggest a benefit of conventional
single-dose stereotactic radiosurgery (SRS). Radio-
surgery with marginal dose or peripheral dose around
12 Gy rarely obliterates AVMs and yet most lesions
diminish in size after SRS. Higher doses may be reap-
plied to any residual nidi after an adequate follow-up
period [64, 76]. However, long-term data show that
some authors retreat the patients with lower doses
with lesions that failed to completely obliterate in the
first place [100; 121].
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segments in order to irradiate them separately. Target
volumes of only 5-15 ml irradiated with doses of
more than 15 Gy can reduce the irradiated volume de-
livered to the surrounding brain tissue [50; 76; 120].
Furthermore, fewer radiation injuries have been re-
ported with fractionated stereotactic radiotherapy
compared to standard radiosurgery [16; 69; 85; 98;
136; 144]. Advances in AVM localization, dose homo-
geneity and dosimetry and fractionated radiotherapy
regimen have refocused the interest in stereotactic ra-
diotherapy. A recently published study of Han et al.
on 218 patients with a follow-up of >2years provides
a focus on the analysis of the radiation injury rate de-
pending on the AVM volume. Investigators dispensed
25 Gy for small (<4 cm3) and medium size (4-14 cm3)
AVMs, and 10 Gy for larger AVMs (>14cm3). The
overall obliteration rate was 66.4 %, 81.7% for small,
53.1% for medium and 12.5% for large AVMs. The
authors reported an acceptable complication rate of
1.7%-17.4%, depending on the size of the AVM [65].
The extended latency period between treatment and
occlusion, about 5 years for emerging techniques (such
as salvage, staged volume, and hypofractionated radio-
therapy), exposes the patient to the risk of haemor-
rhage during that period. Nevertheless, improvements
in dose planning and target delineation will continue
to improve the prognosis in patients suffering from in-
operable AVM’s [16; 69; 85; 98; 136; 144].
OTHER INDICATIONS
Especially in the field of functional neurosurgery
more indications for radiosurgery are emerging. Suc-
cessful treatments of trigeminal neuralgia have been
reported with radiosurgery of the ganglion gasseri in
patients with typical trigeminal neuralgia but also with
facial pain due to multiple sclerosis and petroclival
meningeomas with infiltration of the trigeminal nerve.
Facial pain has become a common indication for ra-
diosurgery with an acceptable rate for hypaesthesia
and a meaningful relief of pain in the vast majority of
the treated patients [88; 105; 118; 119; 125; 132]. The
overall failure rate is about 15%, which is approxi-
mately in the same as for decompression. Chen et al.
identified preoperative factors which can determine
the outcome for pain control: The response to anti-
convulsant medication has been regarded as the single
most important prognostic indicator for treatment
success [3; 23; 53; 54; 59B; 62; 67; 70; 78; 82; 86; 90;
97; 102; 106; 116; 118; 122; 124; 126; 151].
SUMMARY
Radiosurgery is enjoying an increasing popularity since
the last decade in terms of neurosurgical treatment
opportunities but also in terms of treatment options
for brain metastases. External beam and interstitial ra-
diosurgery have been implemented as commonly ap-
plied treatment techniques in radiation oncology as
well as neurosurgery due to significant improvements
in therapy efficacy, technological safety (smaller multi-
leaf collimators), as well as dose homogeneity provid-
ed by the newer LINAC generations and newer gener-
ation radioactive seeds. Technological advances pro-
vide larger treatment flexibility. Apart from the treat-
ment of oncologic processes newer indications also
include the management of AVMs and pain syn-
dromes within the functional neurosurgical field.
Technological advances in stereotactic neurosurgery
not only lead to higher accuracy and safety in planning
of both the target coordinates and trajectories (way to
the target) but also provide superior and sophisticated
methods for defining any intracranial target volume.
Correspondingly, current developments in radio-
surgery are in part a result of the long tradition of
stereotaxy, which today could be considered as an in-
ert component of stereotactic neurosurgery.
In conclusion, the technological advances in radia-
tion oncology as well as stereotactic neurosurgery have
led to significant improvements in radiosurgical treat-
ment opportunities, which will certainly lead to further
expansions in treatment opportunities for radio-
surgery. Combining both, the expertise of the long
tradition of sterotaxy in the field of neurosurgery and
the expertise of highly conformal irradiation in the
field of radiation oncology, will certainly yield to fur-
ther improvements in the treatment success for our
patients, while minimizing the risk for irreversible ra-
diation injuries.
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